Web%20site:%20http://statepi.jhsph.edu/macs/macs.html

1
DOSSIER Updates May 2012

• Web site http//statepi.jhsph.edu/macs/macs.html
• Prepared by CAMACS
• Fax [phone]

The MACS is funded by the National Institute of
Allergy and Infectious Diseases, with additional
supplemental funding from the National Cancer
Institute and the National Heart, Lung and Blood
Institute.   UO1-AI-35042, UL1-RR025005,
UO1-AI-35043, UO1-AI-35039, UO1-AI-35040,
UO1-AI-35041.
May 2011
2
(No Transcript)
3
CAMACS

• Planning and design of studies
• Coordination of data acquisition
• Form development
• Codebooks
• Data transfer
• Standardization and data management
• Edits and updates
• Data security
• Data analysis, statistical computing and
  methodological research

September 1995
4
(No Transcript)
5
, AB (negs)
6
Continuous Outcome Ascertainment

• Seroconversion (seronegatives only)
• Clinical Outcomes (medical records confirmation)
• AIDS diagnoses
• Non-AIDS diagnoses
• Cardiovascular disease
• Cerebrovascular disease
• Kidney disease
• Liver disease
• Lung infection, bacterima, septicemia
• Malignancies
• Neurologic
• Mortality

November 2004
7
(No Transcript)
8
(No Transcript)
9
(No Transcript)
10
Composition Size of Cohort
Participants (thousands)
Visit (Calendar year)
1710 have been administratively censored
May 2011
11
MACS Database(as of May 2012)
Publications (published in press)
11,229 Participants 6,992 Person-Years
89,752 Variables 12,305 Repository
aliquots 1,638,409 (plasma,
serum, cells, urine)
HIV HIV- Person-Visits 58,287
74,588 CD4 Measurements 53,641 59,619 HIV RNA
Measurements 35,822 1,218
May 2012
12
(No Transcript)
13
(No Transcript)
14
(No Transcript)
15
Retention of LA MACS Participants (including
active and those who died through 09/30/07)
HIV- HIV Seroconverters European-American
92.6 94.0 87.3 African-American
67.4 78.6 100 Hispanic-American
76.1 84.3 81 Total 85.3 90.4
87.3 Combined 1530/172888.5
16
Incidence of Seroconversion in the MACS by Center
Kingsley, Zhou, . . ., Muñoz - AJE 1991
(update)
Baltimore Chicago Pittsburgh Los Angeles
Incidence of seroconverters per 1,000
person-semesters
September 1995
17
June 1997
18
Likelihood of Developing AIDS in Three Years
Mellors, Muñoz, . . ., Rinaldo - Ann Int Med
1997
June 1997
19
Proportion Surviving AIDS by Year of
DiagnosisAssumed currently alive at 6/30/99 if
contacted since 6/30/98
Jacobson, Kirby, . . ., Schrager - AJE 1993
(update)
October 1999
20
(No Transcript)
21
MACS Subgroups of Particular Interest

• Long-term seropositive individuals with minimal
  declines in CD4 levels
• Seropositive individuals with rapid declines in
  CD4 levels
• Long-term survivors with low CD4 levels
• Seroconverters
• High-risk seronegatives
• Seropositives on treatment
• gt55 years old

22
Key Factors in the Success of the MACS

• The commitment and sacrifice of the participants
• The staff members of the MACS
• Strong laboratory support

23
UCLA MACS Staff

• John Oishi, Study Coordinator
• Kevin Barrett, Data Manager/Programmer
• Max Hechter, Coordinator
• Charles Doran, Administrative Specialist
• Nicole Hadjioannou, SRA, Clinical Follow-up

24
MACS Clinic Staff

• LA Mens Study, Wilshire Site
• Dennis Miles, Site Manager May Htike, Lead
  ExaminerDaniel Cheng, SRA, Senior
  InterviewerTuan Nguyen, Examiner Alan Ernst,
  InterviewerLos Angeles Gay Lesbian Center
• Eduardo Mercado, Coordinator Ray Mercado,
  Coordinator Harbor-UCLA Medical Center
• Carlos Aquino, Coordinator Lisa Siquieros,
  Assistant CoordinatorGilbert Papilla, Assistant
  Coordinator

25
LA MACS Investigators

• Beth Jamieson Andrew Levine
• John Fahey Jordan Lake
• Anthony Butch Otto Yang
• Steve Young Peter Anton
• Najib Aziz Elizabeth Breen
• Oto Martinez Karl Goodkin
• Rita Effros Mathew Wright
• Barbara Visscher Richard Wight
• Jonathan Braun Pamina Gorbach
• Eric Miller Steve Shoptaw
• Mallory Witt Zuofeng Zhang
• Dorothy Wiley Shenaz Hussain
• Harry Vinters
• Many students